• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Centyrin deal fortifies ties between CAR T partners Poseida and Janssen

Aug. 12, 2015
By Marie Powers
For Poseida Therapeutics Inc., a new global license agreement with Janssen Biotech Inc., a unit of Johnson & Johnson, to discover, develop, manufacture and commercialize chimeric antigen receptor (CAR) T-cell-based therapies is a signal that "everything's unfolding according to plan," observed Eric Ostertag, Poseida's founder and CEO.
Read More

Astrazeneca in I-O three-peat with $727.5M Inovio deal

Aug. 11, 2015
By Marie Powers
Last week, Astrazeneca plc tapped Mirati Therapeutics Inc. for a partnership that will explore a pairing of the spectrum-selective histone deacetylase, or HDAC, blocker mocetinostat with the anti-programmed death-ligand 1 (PD-L1) candidate durvalumab (MEDI4736).
Read More

ADRC therapy: Cytori looks for ECCS-50 to 'STAR' in pivotal phase III scleroderma trial

Aug. 10, 2015
By Marie Powers

LSK doubles down on early oncology pipeline with Huntsman deal

Aug. 10, 2015
By Marie Powers
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Read More

Cytori looks for ECCS-50 to 'STAR' in pivotal phase III scleroderma trial

Aug. 7, 2015
By Marie Powers
The first sites are screening patients in the pivotal U.S. phase III trial of ECCS-50, the adipose-derived regenerative cell (ADRC) therapy developed by Cytori Therapeutics Inc., in the lead indication of scleroderma.
Read More

Metabolic/endocrine mash-up Metacrine lines up $36M series A

Aug. 6, 2015
By Marie Powers
Arch Venture Partners, Ecor1 Capital, Polaris Partners and Venbio lined up behind Metacrine Inc., a start-up seeking to apply endocrine research to metabolic disease.
Read More

Drugs enter third dimension: First FDA approval in hand, Aprecia looks to alter drug delivery with 3-D printing

Aug. 5, 2015
By Marie Powers

First FDA approval in hand, Aprecia looks to alter drug delivery with 3D printing

Aug. 5, 2015
By Marie Powers
The active drug, levetiracetam, isn't new, but FDA approval of Spritam to treat certain forms of epilepsy guaranteed a spot in biopharma history for Aprecia Pharmaceuticals Co., which became the first company to bring a drug product using three-dimensional printing (3DP) through the approval process.
Read More

Awaiting FDA nod, Vonvendi proves mettle in bleeding disorder

Aug. 4, 2015
By Marie Powers
With a biologics license application (BLA) for BAX 111 (vonicog alfa) already pending at the FDA, investigators for the phase III study of the Baxalta Inc. therapy, branded Vonvendi, reported that 100 percent of patients treated with the recombinant, glycosylated von Willebrand factor (PSA-rvWF) achieved success in controlling bleeding.
Read More

Pharmacyte seeks to solve pancreas puzzle with Cell-in-a-Box

Aug. 3, 2015
By Marie Powers
Considering its relatively inconspicuous presence in the body, the pancreas can wreak havoc on human health through two major diseases: diabetes and pancreatic cancer. Both can be deadly – the former from the condition itself or from long-term complications and the latter from advanced disease that may be symptomatic for only months or even weeks. Neither has a cure.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe